Praetego Inc. has been granted a US$300,000 phase I Small Business Technology Transfer Research (STTR) award by the National Eye Institute (NEI) to advance the company's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.
Aldeyra Therapeutics Inc. is eyeing the start of clinical trials with reactive aldehyde species (RASP) modulators ADX-246 for systemic immune-mediated diseases and ADX-248 for geographic atrophy.
Akari Therapeutics plc has advanced its preclinical development program for long-acting PAS-nomacopan for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The company has produced new and promising versions and progressed from lab scale to pre-GMP optimization, and is targeting an IND application to the FDA in the first half of next year.
Researchers from Curacle Co. Ltd. and Yonsei University have published preclinical data for the endothelial dysfunction blocker CU06-1004 from studies assessing it in models of retinal vascular disease.
Exegenesis Bio (Hangzhou Exegenesis Biotechnology Co. Ltd.) has received FDA clearance of its IND application for EXG-102-031, a recombinant adeno-associated virus (rAAV)-based gene therapy that is being studied for the treatment of neovascular age-related macular degeneration (AMD).
National Institute of Pharmaceutical R&D Co. Ltd. has discovered compounds with ability to capture reactive carbonyl species reported to be useful for the treatment of eye disorders, among others.
Traumatic optic neuropathy (TON) is a serious complication combining craniocerebral, orbital and facial injuries. While there is currently no reliable animal model of this condition, it has been previously demonstrated that TON can cause the loss of retinal ganglion cells (RGC). In the current study, researchers from Shanghai Jiaotong University developed a novel mouse model of distal TON, with the aim of assessing the cascade reactions of RGCs in this disease.
Cancer Focus Fund LP is investing US$5 million in funding to support ISA Pharmaceuticals BV's ISA-103 in a first-in-human study for the treatment of uveal melanoma.
RSS
